Clinical Trial Update: Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

Novartis conducted a Phase 2 trial to evaluate the safety and tolerability of incremental doses of QAB149 in adults with mild-to-moderate chronic obstructive pu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• QAB149

Snippet

Sponsor: Novartis | Conditions: COPD | Phase 2 | Status: COMPLETED